RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+5.22%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.61B
AUM Growth
+$6.61B
(-4.3%)
Cap. Flow
-$127M
Cap. Flow
% of AUM
-1.92%
Top 10 Holdings %
Top 10 Hldgs %
48.57%
Holding
77
New
9
Increased
21
Reduced
16
Closed
5
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$84.6M |
| 2 |
Globus Medical
GMED
|
$80.4M |
| 3 |
Stryker
SYK
|
$69.6M |
| 4 |
Zai Lab
ZLAB
|
$65.7M |
| 5 |
Xencor
XNCR
|
$42M |
Top Sells
| 1 |
Geron
GERN
|
$200M |
| 2 |
Masimo
MASI
|
$129M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$91.8M |
| 4 |
Bruker
BRKR
|
$58.6M |
| 5 |
Glaukos
GKOS
|
$50.3M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Spyre Therapeutics
SYRE
$1.02B
| $84.3M | 1.28% |
3,621,996
+363,636
| +11% | +$8.47M |
|
27
Ultragenyx Pharmaceutical
RARE
$3.04B
| $82.8M | 1.25% |
1,968,002
| – | – |
|
|
28
Globus Medical
GMED
$7.94B
| $80.4M | 1.22% |
+972,000
| New | +$80.4M |
|
|
29
Zai Lab
ZLAB
$3.48B
| $65.7M | 0.99% |
+2,509,119
| New | +$65.7M |
|
30
Arvinas
ARVN
$580M
| $63.9M | 0.97% |
3,334,308
+551,979
| +20% | +$10.6M |
|
|
CRGX
31
DELISTED
CARGO Therapeutics
CRGX
| $59.5M | 0.9% |
4,124,859
+25,904
| +0.6% | +$374K |
|
32
89bio
ETNB
$1.37B
| $58.5M | 0.88% |
7,478,061
+99,513
| +1% | +$778K |
|
33
Stoke Therapeutics
STOK
$1.08B
| $56.5M | 0.85% |
5,123,525
+471,240
| +10% | +$5.2M |
|
|
34
Xencor
XNCR
$594M
| $55.2M | 0.84% |
2,402,883
+1,827,883
| +318% | +$42M |
|
35
CG Oncology
CGON
$2.19B
| $48.8M | 0.74% |
1,701,216
+357,142
| +27% | +$10.2M |
|
36
Immatics
IMTX
$662M
| $46.5M | 0.7% |
6,540,540
-3,459,460
| -35% | -$24.6M |
|
37
UroGen Pharma
URGN
$896M
| $40.8M | 0.62% |
3,834,794
+47,447
| +1% | +$505K |
|
|
ORKA
38
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $37.7M | 0.57% |
1,945,649
+95,001
| +5% | +$1.84M |
|
39
Orchestra BioMed
OBIO
$147M
| $32.8M | 0.5% |
8,206,162
+3
| +0% | +$12 |
|
40
Neurogene
NGNE
$284M
| $30.9M | 0.47% |
1,350,256
+215,000
| +19% | +$4.91M |
|
41
Replimune Group
REPL
$460M
| $25M | 0.38% |
2,065,010
+931,223
| +82% | +$11.3M |
|
|
LENZ
42
LENZ Therapeutics
LENZ
$1.12B
| $24.9M | 0.38% |
863,389
| – | – |
|
43
GH Research
GHRS
$870M
| $23.3M | 0.35% |
3,327,129
| – | – |
|
44
Cullinan Oncology
CGEM
$456M
| $20.8M | 0.31% |
1,705,960
| – | – |
|
45
RAPT Therapeutics
RAPT
$187M
| $18.6M | 0.28% |
+11,764,000
| New | +$18.6M |
|
46
Roivant Sciences
ROIV
$8.6B
| $17.2M | 0.26% |
1,454,273
| – | – |
|
|
SAGE
47
DELISTED
Sage Therapeutics
SAGE
| $16.3M | 0.25% |
3,002,370
-2,589,330
| -46% | -$14.1M |
|
48
uniQure
QURE
$954M
| $16M | 0.24% |
903,625
+893,625
| +8,936% | +$15.8M |
|
49
Taysha Gene Therapies
TSHA
$791M
| $15M | 0.23% |
8,672,630
-6,273,790
| -42% | -$10.9M |
|
50
Tourmaline Bio
TRML
$645M
| $14.9M | 0.23% |
736,681
-4,975
| -0.7% | -$101K |
|